

Introduction


The 5th nationwide surveillance of bacterial respiratory pathogens in 2010 has been executed by a team of three academic societies of Japan.

Materials & Methods

- 1) Surveillance period: January - September, 2010
- 2) Cooperative institutes: 33 Hospitals throughout Japan.
- 3) Strains tested: Isolated from sputum, trans-tracheal aspirates (TTA) including bronchoscopy (identified by qualitative culture and Gram-staining etc) of adult patients who was well-diagnosed as respiratory tract infection(RTI) [community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), acute exacerbations of chronic respiratory diseases (AECRD), and others].
- 4) Antibacterial agents tested: 42 agents as listed in Table 2.
- 5) Susceptibility test: Conducted at the surveillance central laboratory (Kitasato University, Lab. for Antimicrob. Agents) according to the CLSI standards for broth microdilution methods.
- 6) For classification of penicillin susceptibility in *Streptococcus pneumoniae*, M-100 S-17 (January, 2007) was employed.
- 7) Determination of β -lactamase: Nitrocefin method for detection of *Haemophilus influenzae* penicillinase.



Table 1 Number of bacterial strains tested

Bacterial species	2006	2007	2008	2009	2010
<i>Staphylococcus aureus</i>	205	226	189	130	206
<i>Streptococcus pneumoniae</i>	200	257	211	127	190
<i>Streptococcus pyogenes</i>	9	6	6	4	4
<i>Moraxella catarrhalis</i>	91	120	106	70	74
<i>Haemophilus influenzae</i>	165	206	187	123	182
<i>Klebsiella pneumoniae</i>	74	122	126	78	139
<i>Pseudomonas aeruginosa</i>	143	171	162	103	160
Total	887	1108	987	635	955

Fig.1 Proportions of MRSA and MSSA isolated in past five years

MSSA: Oxacillin susceptible *Staphylococcus aureus*, MIC of Oxacillin \leq 2 μ g/mL

MRSA: Oxacillin resistant *Staphylococcus aureus*, MIC of Oxacillin \geq 4 μ g/mL

Fig.2 Proportions of PSSP,PISP and PRSP isolated in past five years**Fig.3 Proportions of BLNAS,BLNAI,BLNAR and BLPAR isolated in past five years**

BLNAS: β -lactamase negative ampicillin susceptible *Haemophilus influenzae*, MIC of Ampicillin \leq 1 μ g/mL

BLNAI: β -lactamase negative ampicillin intermediate *Haemophilus influenzae*, MIC of Ampicillin = 2 μ g/mL

BLNAR: β -lactamase negative ampicillin resistant *Haemophilus influenzae*, MIC of Ampicillin \geq 4 μ g/mL

BLPAR: β -lactamase positive ampicillin resistant *Haemophilus influenzae*, MIC of Ampicillin \geq 4 μ g/mL

Table 2 Susceptibility of 3 major respiratory pathogens to antibacterial agents [MIC₉₀(μ g/mL)]

Antibacterial agent	<i>Staphylococcus aureus</i>				2006	2010	n = 165	n = 182
	MSSA		MRSA					
	2006	2010	2006	2010	2006	2010	n = 200	n = 190
Penicillin G	16	8	64	32	1	2	8	32
Ampicillin	16	4	64	32	2	2	8	32
Ampicillin-sulbactam	2	1	32	32	2	2	4	8
Amoxicillin-clavulanic acid	2	1	32	32	1	1	8	8
Piperacillin	32	8	\geq 256	\geq 256	2	2	0.25	1
Piperacillin-tazobactam	2	1	\geq 256	\geq 256	2	2	0.125	0.125
Cefaclor	4	2	\geq 256	\geq 256	32	64	64	64
Cefdinir	0.5	0.5	\geq 128	\geq 128	4	4	8	8
Cefcapene	1	1	\geq 256	\geq 256	0.5	0.5	1	2
Cefditoren	1	1	\geq 128	\geq 128	0.25	0.25	0.25	0.25
Cefazolin	1	0.5	\geq 256	\geq 256	2	2	128	128
Cefmetazole	2	1	64	128	4	16	8	32
Cefotiam	1	1	\geq 256	\geq 256	2	4	64	64
Ceftazidime	8	8	\geq 128	\geq 128	8	8	8	8
Ceftriaxon	4	4	\geq 256	\geq 256	1	1	0.5	0.5
Cefepime	4	2	\geq 256	\geq 256	1	1	2	2
Cefozopran	1	1	64	64	1	1	16	16
Imipenem	\leq 0.06	\leq 0.06	64	64	0.125	0.25	4	2
Panipenem	\leq 0.06	\leq 0.06	32	32	\leq 0.06	0.125	2	2
Meropenem	0.125	0.125	32	32	0.25	0.25	0.5	0.25
Biapenem	\leq 0.06	\leq 0.06	64	64	0.25	0.25	8	4
Doripenem	\leq 0.06	\leq 0.06	16	16	0.25	0.25	1	1
Faropenem	—	0.125	—	—	\geq 256	—	0.25	—
Aztreonam	—	—	—	—	—	—	2	2
Gentamicin	32	8	128	64	8	8	1	2
Tobramycin	—	8	—	\geq 256	—	32	—	4
Amikacin	8	4	32	16	128	64	8	8
Arbekacin	1	0.5	2	1	32	32	4	4
Erythromycin	\geq 256	\geq 256	\geq 256	\geq 256	\geq 256	\geq 256	4	8
Clarithromycin	\geq 128	\geq 128	\geq 128	\geq 128	\geq 128	\geq 128	8	8
Azithromycin	\geq 128	\geq 128	\geq 128	\geq 128	\geq 128	\geq 128	1	2
Telithromycin	0.25	—	\geq 64	—	0.25	—	2	—
Ciprofloxacin	1	1	\geq 256	\geq 256	2	2	\leq 0.06	\leq 0.06
Levofloxacin	0.5	0.5	\geq 256	\geq 256	2	2	\leq 0.06	\leq 0.06
Tosufloxacin	0.25	0.125	\geq 32	\geq 32	0.25	0.25	\leq 0.06	\leq 0.06
Gatifloxacin	0.125	—	64	—	0.5	—	\leq 0.06	—
Moxifloxacin	—	0.125	32	—	0.25	—	\leq 0.06	\leq 0.06
Pazufloxacin	0.25	0.25	\geq 256	\geq 256	2	4	\leq 0.06	\leq 0.06
Garenoxacin	—	\leq 0.06	32	—	\leq 0.06	—	\leq 0.06	\leq 0.06
Sifatloxacin	—	\leq 0.06	8	—	\leq 0.06	—	\leq 0.06	\leq 0.06
Minocycline	0.25	0.125	16	16	8	32	0.5	0.5
Clindamycin	0.5	0.2						